Endocyte Inc., of West Lafayette, Ind., said it closed an underwritten registered public offering of 10.87 million shares, which includes the full exercise of the underwriters' option to purchase additional shares of common stock, at $18.50 per share, for net proceeds of approximately $188.7 million, which it intends to use to fund the continued clinical development of its pipeline products and preparation for the commercial launch of 177Lu-PSMA-617, if approved, as well as for working capital and general corporate purposes.